PureFDA reveals completion of Series B fund
Recently, PureFDA Medical Technology (Guangzhou) Co., LTD. (hereinafter referred to as “PureFDA”) announced the completion of the Series B round of financing of over CNY100 million, which was led by Legend Capital and followed by the existing shareholder Bayland Capital. This round of funds will mainly be used for the construction of overseas medical device […]
Giant Biogene listed on the Hong Kong Stock Exchange
On November, 2022, Legend Capital portfolio company Giant Biogene (2367.HK) was successfully listed on the main board of the Hong Kong Stock Exchange. The number of Giant Biogene’s offer shares under the global offering is 22,608,800 shares at an issue price of HKUSD24.3 per share, which includes 2,261,200 Hong Kong offering shares, 20,347,600 international offering […]
